Literature DB >> 25539484

Clinical characteristics of IgA nephropathy associated with low complement 4 levels.

Bin Zhu1, Cai-Feng Zhu, Yi Lin, Vlado Perkovic, Xian-Fa Li, Ru Yang, Xuan-Li Tang, Xiao-Ling Zhu, Xiao-Xia Cheng, Qiang Li, Hong-Yu Chen, Yue Sun, Qian-Wen Chen, Yong-Jun Wang.   

Abstract

OBJECTIVE: C4 deficiency is the most commonly inherited immune disorder in human. The present study investigated the characteristics of the IgAN patients with low serum C4 levels.
METHODS: We performed a prospective observational study. Clinical as well as histopathologic parameters were assessed. A Kaplan-Meier survival analysis was performed concerning the primary outcome defined as the serum creatinine increased 1.5-fold from baseline. The prognostic significances of clinical and histopathologic parameters were determined using Cox proportional hazards models.
RESULTS: Five-hundred twelve biopsy proven IgAN cases were available for analysis with a median follow-up of 38.4 months. Ninety-nine cases (19.34%) presented with low C4 levels (LowC4 group) and the other 413 cases did not (NlowC4 group). At the time of renal biopsy, renal injury was lighter in the LowC4 group compared with the NlowC4 group. Renal C4 deposition was significantly decreased while IgM deposition was increased in the LowC4 group. A correlation analysis shows that lower C4 levels were associated with better renal presentations at biopsy. However, the risk of developing the primary outcome was significantly greater in those with low C4 levels. Specifically, during the follow-up period, the risk of developing primary outcome was nearly ten folds higher in those with low C4, compared to those without low C4.
CONCLUSION: There is a high prevalence of low C4 levels in IgAN patients. These patients with low C4 levels exhibited better renal presentations at the time of renal biopsy, whereas might be associated with a poor prognosis.

Entities:  

Keywords:  Complement component 4; IgA nephropathy; complement pathway; lectin

Mesh:

Substances:

Year:  2014        PMID: 25539484     DOI: 10.3109/0886022X.2014.994408

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  6 in total

1.  Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.

Authors:  Min Pan; QiongXiu Zhou; ShuBei Zheng; XiaoHan You; Duo Li; Ji Zhang; ChaoSheng Chen; FeiFei Xu; ZhanYuan Li; ZhiHong Zhou; JianNa Zhang
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Mesangial IgM deposition predicts renal outcome in patients with IgA nephropathy: a multicenter, observational study.

Authors:  Li Tan; Yi Tang; Gai-Qin Pei; Zheng-Xia Zhong; Jia-Xing Tan; Ya Ma; Dong-Guang Wang; Ling Zhou; David Sheikh-Hamad; Wei Qin
Journal:  Clin Exp Med       Date:  2021-04-10       Impact factor: 3.984

3.  Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study.

Authors:  Min Pan; Ji Zhang; Zhanyuan Li; Lingwei Jin; Yu Zheng; Zhihong Zhou; Su Zhen; Guoyuan Lu
Journal:  BMC Nephrol       Date:  2017-07-11       Impact factor: 2.388

4.  Glomerular C4 deposition and glomerulosclerosis predict worse renal outcomes in Chinese patients with IgA nephropathy.

Authors:  Yan Yang; Xi Tang; Yuan Yang; Xinrui Li; Lingzhi Li; Kai Huang; Yi Li; Jing Li; Ping Fu
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

5.  Serum complement C4 is an important prognostic factor for IgA nephropathy: a retrospective study.

Authors:  Tong-Dan Bi; Jian-Nan Zheng; Jun-Xiao Zhang; Long-Shu Yang; Nan Liu; Li Yao; Lin-Lin Liu
Journal:  BMC Nephrol       Date:  2019-07-04       Impact factor: 2.388

6.  Relationship between serum C3/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching.

Authors:  Yan Zhang; Shu-Wei Duan; Pu Chen; Zhong Yin; Yong Wang; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Chin Med J (Engl)       Date:  2020-03-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.